Evaluation of neuroprotective effect of Resveratrol during acute ischemic stroke on neurologic deficit

Investigation the effectiveness and non-effectiveness of Resveratrol neuroprotective material during acute phase of ischemic stroke on neurologic deficiency

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016061328430N1

Enrollment

100

Registered

2017-09-09

Start date

2017-09-11

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke. Cerebral infarction

Interventions

Intervention 1: The intervention group, in addition to routine stroke treatments, will receive Resveratrol 500 mg daily for 30 days. Intervention 2: Treatment: drugs Treatment: drugs The control group

Treatment - Drugs

Placebo

The intervention group, in addition to routine stroke treatments, will receive Resveratrol 500 mg daily for 30 days.

Treatment: drugs Treatment: drugs The control group, in addition to routine stroke treatments, will receive 500 mg of placebo daily for 30 days in the form of powdered capsules.

Eligibility

Sex/Gender

All

Age

45 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 45 and 90 years; Diagnosis of ischemic stroke in MCA territory Exclusion criteria: Pregnancy; Referral of the patient for more than 24 hours after start of symptoms; Patients who have received RtPA; Brain hemorrhage and previous stroke.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood pressure. Timepoint: Before the start of the study, upon discharge and three months after the discharge. Method of measurement: Using the barometer device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Sajedeh asgharzadeh

Kermanshah University of Medical Sciences

s.asgharzadeh@yahoo.com+98 83 3427 6301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026